Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%

Novo Nordisk's CEO defended the economics of its Wegovy pill even as lower prices weigh on sales. The stock fell five percent. According to CNBC, Wall Street remains skeptical the Ozempic maker can sustain growth amid intensifying competition from Eli Lilly.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton